Target-identification

Our research aims to identify new target proteins, which could serve as potential targets for pharmacological intervention to treat symptoms of cardiovascular disease. We apply whole genome microarray gene expression profiling of experimental disease models to identify potential candidate genes with disease relevance.

For target identification we perform transgenic model generation. The transgenic model is the final proof of concept for the involvement of a candidate gene in disease pathogenesis.

Since 2012, we generated over 30 different transgenic disease models, which were deposited to repositories (JAX, Janvier). The registered ILAR labcode of MolPharm for transgenic model generation is "Sjaa".